Arecor receives $0.5m milestone from Ligand deal
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arecor Therapeutics PLC (AREC)
Arecor Therapeutics PLC stock price live, this page displays LON AREC stock exchange data. View the AREC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arecor Therapeutics PLC real time stock price chart below.
What Is the Arecor Therapeutics PLC Stock Price Today?
The Arecor Therapeutics PLC stock price today is 66.00.
What Is the Stock Symbol for Arecor Therapeutics PLC?
The stock symbol for Arecor Therapeutics PLC is "AREC."
What Stock Exchange Does Arecor Therapeutics PLC Trade On?
Arecor Therapeutics PLC is listed and trades on the London stock exchange.
Is Arecor Therapeutics PLC a Good Stock to Buy?
Determining whether Arecor Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AREC quote. (ISIN: GB00BMWLM973)
What Is the Arecor Therapeutics PLC Stock Price Today?
The Arecor Therapeutics PLC stock price today is 66.00.
What Is the Stock Symbol for Arecor Therapeutics PLC?
The stock symbol for Arecor Therapeutics PLC is "AREC."
What Stock Exchange Does Arecor Therapeutics PLC Trade On?
Arecor Therapeutics PLC is listed and trades on the London stock exchange.
Is Arecor Therapeutics PLC a Good Stock to Buy?
Determining whether Arecor Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AREC quote. (ISIN: GB00BMWLM973)
London
Currency in GBP
66.00
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
66.00
70.00
52 wk Range
36.60
100.00
AREC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
66.0070.00
52 wk Range
36.60100.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
AREC Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
275.50
Upside
+317.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Compare AREC to Peers and Sector
Metrics to compare | AREC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARECPeersSector | |
|---|---|---|---|---|
P/E Ratio | 26.7x | −8.4x | −0.4x | |
PEG Ratio | 0.25 | −0.12 | 0.00 | |
Price/Book | 3.9x | 2.7x | 2.6x | |
Price / LTM Sales | 14.5x | 6.5x | 3.2x | |
Upside (Analyst Target) | 317.4% | 134.0% | 45.4% | |
Fair Value Upside | Unlock | 0.8% | 7.0% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 275.50
(+317.42% Upside)
Earnings
Latest Release
Apr 13, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
FAQ
What Is the Arecor Therapeutics (AREC) Stock Price Today?
The Arecor Therapeutics stock price today is 66.00 GBP.
What Stock Exchange Does Arecor Therapeutics Trade On?
Arecor Therapeutics is listed and trades on the London Stock Exchange.
What Is the Stock Symbol for Arecor Therapeutics?
The stock symbol for Arecor Therapeutics is "AREC."
What Is the Arecor Therapeutics Market Cap?
As of today, Arecor Therapeutics market cap is 24.92M GBP.
What Is Arecor Therapeutics's Earnings Per Share (TTM)?
The Arecor Therapeutics EPS (TTM) is 0.02.
When Is the Next Arecor Therapeutics Earnings Date?
Arecor Therapeutics will release its next earnings report on Apr 13, 2026.
From a Technical Analysis Perspective, Is AREC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Arecor Therapeutics Stock Split?
Arecor Therapeutics has split 0 times.
How Many Employees Does Arecor Therapeutics Have?
Arecor Therapeutics has 44 employees.
What is the current trading status of Arecor Therapeutics (AREC)?
As of Apr 22, 2026, Arecor Therapeutics (AREC) is trading at a price of 66.00 GBP, with a previous close of 66.00 GBP. The stock has fluctuated within a day range of 66.00 GBP to 70.00 GBP, while its 52-week range spans from 36.60 GBP to 100.00 GBP.
What Is Arecor Therapeutics (AREC) Price Target According to Analysts?
The average 12-month price target for Arecor Therapeutics is 275.50 GBP, with a high estimate of 300 GBP and a low estimate of 251 GBP. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +317.42% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.